Pfizer to Share Overseas Drug Revenue with US Under New HHS Contract

Key Facts

1Pfizer has entered a new contract with the U.S. Department of Health and Human Services to share a higher portion of drug revenue generated overseas.

Reflecting evolving U.S. healthcare policy dynamics, Pfizer has reportedly reached an agreement with the U.S. Department of Health and Human Services (HHS). According to reports, the new contract stipulates that the company will share a higher portion of drug revenue generated in overseas markets with the U.S. government. This move likely aligns with federal initiatives regarding drug pricing and revenue sharing for products developed under government support.

The development comes as markets assess the potential impact on Pfizer's net international revenue retention, although the exact financial magnitude remains unspecified in initial reports. Per market data, the outlook remains mixed as the company navigates the balance between these new sharing requirements and its global pricing strategies.

At the close on September 18, 2026, PFE shares stood at $27.66, having traded between a day high of $27.66 and a low of $27.34. Investors are monitoring for further contractual details, while recent economic data showed a softening in the U.S. NY Empire State Manufacturing Index, which fell to 7.6 on September 15.